KR20010042322A - 막-유형 매트릭스 메탈로프로테인아제를 억제하는 방법 - Google Patents

막-유형 매트릭스 메탈로프로테인아제를 억제하는 방법 Download PDF

Info

Publication number
KR20010042322A
KR20010042322A KR1020007010871A KR20007010871A KR20010042322A KR 20010042322 A KR20010042322 A KR 20010042322A KR 1020007010871 A KR1020007010871 A KR 1020007010871A KR 20007010871 A KR20007010871 A KR 20007010871A KR 20010042322 A KR20010042322 A KR 20010042322A
Authority
KR
South Korea
Prior art keywords
cmt
tetracycline
mmp
activity
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020007010871A
Other languages
English (en)
Korean (ko)
Inventor
골룹론엠
리시-밍
조르자티모
테로넨올리
잘로투울라
Original Assignee
제임스 알. 데니히
더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 알. 데니히, 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 filed Critical 제임스 알. 데니히
Publication of KR20010042322A publication Critical patent/KR20010042322A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020007010871A 1998-03-31 1999-03-30 막-유형 매트릭스 메탈로프로테인아제를 억제하는 방법 Ceased KR20010042322A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9/052,222 1998-03-31
US09/052,222 US6277061B1 (en) 1998-03-31 1998-03-31 Method of inhibiting membrane-type matrix metalloproteinase
PCT/US1999/006972 WO1999049871A1 (en) 1998-03-31 1999-03-30 Method of inhibiting membrane-type matrix metalloproteinase

Publications (1)

Publication Number Publication Date
KR20010042322A true KR20010042322A (ko) 2001-05-25

Family

ID=21976191

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007010871A Ceased KR20010042322A (ko) 1998-03-31 1999-03-30 막-유형 매트릭스 메탈로프로테인아제를 억제하는 방법

Country Status (8)

Country Link
US (2) US6277061B1 (cg-RX-API-DMAC7.html)
EP (1) EP1079837A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002509889A (cg-RX-API-DMAC7.html)
KR (1) KR20010042322A (cg-RX-API-DMAC7.html)
AU (1) AU748870B2 (cg-RX-API-DMAC7.html)
CA (1) CA2320260A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ506153A (cg-RX-API-DMAC7.html)
WO (1) WO1999049871A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506740B1 (en) * 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
EP1174129A1 (en) * 2000-07-17 2002-01-23 Zenner, Hans Peter, Prof. Dr. med. Use of a matrix-metalloprotease inhibitor for the treatment of cancer
EP1408987B1 (en) 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
WO2003030819A2 (en) * 2001-10-05 2003-04-17 Tetragenex Pharmaceuticals, Inc. Tetracycline derivatives and methods of use thereof
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
WO2003053447A1 (en) * 2001-12-20 2003-07-03 Hanauske-Abel Hartmut M Treatment for averting or delaying premature delivery
EP2311797A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
JP2005526754A (ja) 2002-03-08 2005-09-08 パラテック ファーマシューティカルズ インコーポレイテッド アミノメチル置換されたテトラサイクリン化合物
EP1503981A4 (en) 2002-03-21 2007-08-15 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS
WO2003082011A1 (en) * 2002-03-29 2003-10-09 The Research Foundation Of State University Of New York Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins
WO2004006850A2 (en) 2002-07-12 2004-01-22 Paratek Pharmaceuticals, Inc 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
US20040170621A1 (en) * 2002-08-30 2004-09-02 Roodman G. David Method of resisting osteoclast formation
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
JP4686189B2 (ja) 2002-10-24 2011-05-18 パラテック ファーマシューティカルズ インコーポレイテッド Rnaを調節するための置換テトラサイクリン化合物の使用方法
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2005009943A2 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP4738333B2 (ja) 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド 9−アミノメチルテトラサイクリン化合物のプロドラッグ
EP2332904A3 (en) * 2004-01-15 2012-04-11 Paratek Pharmaceuticals, Inc. Derivatives of tetracycline compounds
JP2008518025A (ja) 2004-10-25 2008-05-29 パラテック ファーマシューティカルズ インコーポレイテッド 4−アミノテトラサイクリンおよびその使用の方法
WO2006047756A2 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2616224A1 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
US20070142337A1 (en) * 2005-12-15 2007-06-21 The Regents Of The University Of California Treatment of inflammation and organ dysfunction
PL2120963T3 (pl) 2006-12-21 2019-05-31 Paratek Pharm Innc Podstawione związki tetracyklinowe do leczenia zaburzeń zapalnych skóry
IL270446B2 (en) * 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
EP2144870A2 (en) * 2007-04-27 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
WO2009009042A1 (en) * 2007-07-06 2009-01-15 Paratek Pharmaceuticals, Inc. Methods for synthesizing substituted tetracycline compounds
TWI585071B (zh) 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
HUE026562T2 (hu) 2008-08-08 2016-06-28 Tetraphase Pharmaceuticals Inc C7-fluor-helyettesített tetraciklin vegyületek
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
EP2470500B1 (en) 2009-08-28 2017-10-04 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
WO2011123536A1 (en) 2010-03-31 2011-10-06 Tetraphase Pharmaceuticals, Inc. Polycyclic tetracycline compounds
LT2707003T (lt) 2011-05-12 2019-10-10 Paratek Pharmaceuticals, Inc. Kristalinės (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksirūgšties amido druskos ir jų panaudojimo būdai
TR201902057T4 (tr) 2012-08-31 2019-03-21 Tetraphase Pharmaceuticals Inc Tetrasiklin bileşikleri.
MA46567A (fr) 2016-10-19 2019-08-28 Tetraphase Pharmaceuticals Inc Formes cristallines de l'éravacycline
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704383A (en) * 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
AU1411992A (en) 1991-01-15 1992-08-27 Robert A Bok A composition containing a tetracycline and use for inhibiting angiogenesis
JPH06256280A (ja) * 1992-11-17 1994-09-13 Univ New York State 糖尿病における過度のコラーゲン架橋結合を阻害する非抗菌性化学修飾テトラサイクリンを含むテトラサイクリン
US5668122A (en) * 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
GB9615976D0 (en) 1996-07-30 1996-09-11 Center For Clinical & Basic Re The use of proteinase inhibitors for the prevention or reduction of bone resorption
US5789395A (en) * 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth

Also Published As

Publication number Publication date
NZ506153A (en) 2003-10-31
AU3457699A (en) 1999-10-18
US6277061B1 (en) 2001-08-21
US20020045603A1 (en) 2002-04-18
WO1999049871A8 (en) 1999-12-02
CA2320260A1 (en) 1999-10-07
AU748870B2 (en) 2002-06-13
JP2002509889A (ja) 2002-04-02
WO1999049871A1 (en) 1999-10-07
EP1079837A4 (en) 2003-07-02
EP1079837A1 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
US6277061B1 (en) Method of inhibiting membrane-type matrix metalloproteinase
JP4428727B2 (ja) 癌の成長を抑制する方法
ES2237945T3 (es) Combinacion de bisfosfonato y tetraciclina.
US6384081B2 (en) Treatment of diseases of the eye characterized by the formation of metalloproteinase
ES2241124T3 (es) Actividad inhibidora de serin-proteinasa mediante tetraciclina hidrofoba.
Hagmann et al. Inhibition of matrix metalloproteinases.
Scory et al. Trypanosoma brucei: Killing of Bloodstream Formsin Vitroandin Vivoby the Cysteine Proteinase Inhibitor Z-Phe-Ala-CHN2
Lee et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer
US6429204B1 (en) Method of inhibiting cancer growth
JP2002506881A (ja) 新規マトリックスメタロプロテイナーゼ阻害剤および下方調節剤
US20070027064A1 (en) Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
US6033664A (en) Use of a preparation comprising a plasminogen activator to improve wound healing
JP2005535674A (ja) 線維症および瘢痕形成の治療におけるコンバターゼインヒビターの使用
Hanemaaijer et al. Inhibition of matrix metalloproteinases (MMPs) by tetracyclines
US20180311364A1 (en) Protease Triggered Release Of Molecules From Hydrogels
US20180028672A1 (en) Protease Triggered Release Of Molecules From Hydrogels
MXPA99006554A (en) Method of inhibiting cancer growth
Riedlinger et al. Metastatic melanoma and matrix metalloproteinases
Acid Correlation of Antiangiogenic and Antitumor Efficacy of
WO1996016648A1 (en) Method for regulating metalloproteinase activity
Hagmann SmithKline Beecham Pharmaceuticals2, King of Prussia, PA19406
Anand Function and Regulation of Matrix Metalloproteinase-1 in Glioblastoma Multiforme

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20000929

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20040329

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20051209

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20060518

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20051209

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20060818

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20060518

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20070725

Appeal identifier: 2006101007268

Request date: 20060818

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20060818

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20060818

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20060309

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20040329

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20060818

Effective date: 20070725

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20070725

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20060818

Decision date: 20070725

Appeal identifier: 2006101007268